GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $15.51 million. The enterprise value is $6.58 million.

Market Cap	15.51M
Enterprise Value	6.58M

Important Dates

The next estimated earnings date is Thursday, August 13, 2026, after market close.

Earnings Date	Aug 13, 2026
Ex-Dividend Date	n/a

Share Statistics

GT Biopharma has 36.06 million shares outstanding. The number of shares has increased by 484.42% in one year.

Current Share Class	36.06M
Shares Outstanding	36.06M
Shares Change (YoY)	+484.42%
Shares Change (QoQ)	+133.34%
Owned by Insiders (%)	6.94%
Owned by Institutions (%)	5.18%
Float	33.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.00
P/TBV Ratio	2.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.14

Current Ratio	4.14
Quick Ratio	3.69
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-70.20

Financial Efficiency

Return on equity (ROE) is -921.55% and return on invested capital (ROIC) is -252.61%.

Return on Equity (ROE)	-921.55%
Return on Assets (ROA)	-131.76%
Return on Invested Capital (ROIC)	-252.61%
Return on Capital Employed (ROCE)	-175.96%
Weighted Average Cost of Capital (WACC)	8.98%
Revenue Per Employee	n/a
Profits Per Employee	-$37.04M
Employee Count	1
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.20% in the last 52 weeks. The beta is 0.86, so GT Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-87.20%
50-Day Moving Average	0.40
200-Day Moving Average	0.57
Relative Strength Index (RSI)	48.51
Average Volume (20 Days)	1,622,231

Short Selling Information

The latest short interest is 2.00 million, so 5.54% of the outstanding shares have been sold short.

Short Interest	2.00M
Short Previous Month	2.08M
Short % of Shares Out	5.54%
Short % of Float	5.96%
Short Ratio (days to cover)	0.95

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-13.34M
Pretax Income	-30.41M
Net Income	-37.04M
EBITDA	n/a
EBIT	-13.34M
Earnings Per Share (EPS)	-$2.96

Full Income Statement

Balance Sheet

The company has $8.92 million in cash and n/a in debt, giving a net cash position of $8.92 million or $0.25 per share.

Cash & Cash Equivalents	8.92M
Total Debt	n/a
Net Cash	8.92M
Net Cash Per Share	$0.25
Equity (Book Value)	7.58M
Book Value Per Share	0.22
Working Capital	7.58M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-13.18M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	-13.18M
FCF Per Share	-$0.37

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-484.42%
Shareholder Yield	-484.42%
Earnings Yield	-238.87%
FCF Yield	-84.99%

Analyst Forecast

The average price target for GT Biopharma is $3.00, which is 597.67% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	597.67%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.

Last Split Date	Feb 5, 2024
Split Type	Reverse
Split Ratio	1:30

Scores

Altman Z-Score	n/a
Piotroski F-Score	2